EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases
    1.
    发明授权
    EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases 失效
    EGLN2变体及其在预防或治疗血栓栓塞性疾病和冠心病中的用途

    公开(公告)号:US08211427B2

    公开(公告)日:2012-07-03

    申请号:US13015994

    申请日:2011-01-28

    CPC分类号: C12N9/0071

    摘要: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.

    摘要翻译: 本发明涉及具有丝氨酸或亮氨酸的氨基酸序列58位的人EGLN2变异体及其在预防或治疗血栓栓塞或冠心病,特别是中风,长期可逆性缺血性神经功能缺损(PRIND), 经皮缺血发作(TIA),心肌梗死和/或早期心肌梗死。

    Two-color differential display as a method for detecting regulated genes
    5.
    发明授权
    Two-color differential display as a method for detecting regulated genes 失效
    双色差示显示法作为检测调控基因的方法

    公开(公告)号:US06645741B2

    公开(公告)日:2003-11-11

    申请号:US10015593

    申请日:2001-12-17

    IPC分类号: C12P1934

    摘要: The invention relates to a novel method for analyzing the composition of an mRNA sample and analyzing differential gene expression using two differently labeled primers, and to the use of the method. In the method for analyzing an RNA sample, a) a first primer, which is, where appropriate, labeled with a first dye, is used to prepare the first strand of a complementary DNA sample or cDNA sample from an RNA sample, b) a second primer, which is preferably labeled with a second dye, is used to prepare the second strand of this cDNA sample, c) the first primer, which is labeled with a first dye, and the second primer, which is labeled with a second dye, are used to amplify the cDNA sample, and d) the composition of the amplified, labeled cDNA sample is analyzed.

    摘要翻译: 本发明涉及一种用于分析mRNA样品的组成并使用两个不同标记的引物分析差异基因表达的新方法以及该方法的使用。在分析RNA样品的方法中,a)第一引物,其中 在适当的情况下用第一染料标记,用于从RNA样品制备互补DNA样品或cDNA样品的第一条链,b)优选用第二染料标记的第二引物用于制备 该cDNA样品的第二条链,c)用第一染料标记的第一引物,用第二染料标记的第二引物用于扩增cDNA样品,并且d)扩增的 分析标记的cDNA样品。

    EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES
    6.
    发明申请
    EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES 失效
    EGLN2变异体及其在预防或治疗血栓性疾病和冠状动脉疾病中的应用

    公开(公告)号:US20110123515A1

    公开(公告)日:2011-05-26

    申请号:US13015994

    申请日:2011-01-28

    CPC分类号: C12N9/0071

    摘要: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.

    摘要翻译: 本发明涉及具有丝氨酸或亮氨酸的氨基酸序列58位的人EGLN2变异体及其在预防或治疗血栓栓塞或冠心病,特别是中风,长期可逆性缺血性神经功能缺损(PRIND), 经皮缺血发作(TIA),心肌梗死和/或早期心肌梗死。

    Method of Diagnosis of a Predisposition to Develop Thrombotic Disease and Its Uses
    9.
    发明申请
    Method of Diagnosis of a Predisposition to Develop Thrombotic Disease and Its Uses 失效
    诊断血栓形成疾病倾向的方法及其应用

    公开(公告)号:US20080038722A1

    公开(公告)日:2008-02-14

    申请号:US10592692

    申请日:2005-03-16

    IPC分类号: C12Q1/68

    CPC分类号: C12Q1/6883 C12Q2600/156

    摘要: The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P2X1 promoter variant and its use for screening for an anti-thrombotic agent, and to methods for identifying an individual that can be prophylactically or therapeutically treated with an anti-thrombotic agent, or for adapting a therapeutic or prophylactic dose of an anti-thrombotic agent.

    摘要翻译: 本发明涉及诊断发生血栓形成疾病的倾向,测试系统及其用于诊断倾向于发展血栓形成性疾病的用途的方法,以诊断P 启动子变体及其用于筛选抗血栓形成剂的用途,以及用于鉴定可以用抗血栓形成剂预防性或治疗性治疗的个体的方法,或用于调整治疗或预防剂量的抗血栓形成剂 血栓形成剂。